Q Shield™ Hand and Surface Products
Our products help kill many common germs. These patented solutions were created to help healthcare staff and organizations proactively protect against infection.
Axenic™ works to help customers reduce infections by controlling the spread of pathogens through a combination of products, services, and technology.
CDC reports suggest that 1:31 hospital patients contract a healthcare-acquired infection (HAI). These infections result in lost lives and high healthcare spending each year. The industry-wide shift toward value-based care warrants an increased focus on these types of costly issues.
This shift means that hospitals and health systems have to consider the real value of the care they provide instead of simply expecting direct reimbursement for patient care. In general, costs associated with HAIs are not reimbursable under new care models, and money spent treating HAIs does not go back into patient care.
These factors combine to enhance HAI reduction efforts, which have historically relied on reactive tools, measures, and protocols. We provide hospitals with the resources they need to take a proactive step toward reducing HAIs.
Wound care costs the U.S. healthcare system up to $25 billion each year. Wound-related infections are often the most expensive complications following surgery and continue to be a significant contributor to infection rates.
As the average life expectancy increases with advances in modern medicine, the number of chronic disease patients also continues to rise. Accordingly, the demand for effective wound care services is likely to also continue to increase.
Bloodstream and other types of infections are a significant threat and one of the leading causes of death for hemodialysis patients. Many bloodstream infections occur among hemodialysis patients with central lines. These patients may experience adverse complications as a result of their infection.
With a shift in focus to value-based care and reimbursement rates that will be determined by patient outcomes, dialysis center reimbursements can be jeopardized by poor infection management practices. Facilities that see high levels of HAIs may be at risk of lower value-based ratings. Since 1993, hospitalization rates among hemodialysis patients have increased for both bloodstream infections and vascular access infections.
In cleanroom environments, humans are the primary source of contamination. Tainted environments or materials create insanitary conditions and can even contribute to contamination of medications. Apart from the risk of serious infection or death to patients, contamination can lead to recalls, regulatory observations and fines, increased downtime for remediation, or diminish the medication’s overall effectiveness.
Over the past decade, several contamination events within specialty pharmacy manufacturers across the country have raised urgent alarms over the adequacy of contamination management products and practices. Limited monitoring capabilities and liberal compliance processes that allow room for human error can all contribute to the growing insanitary conditions of a cleanroom, leaving them at risk of harboring deadly pathogens.
Providing you with the knowledge and tools you need to better reduce HAIs